Neil Kumar sold $6.0M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $74.61, traded Apr 9, 2026, filed Apr 13, 2026.
Score components
- +25RoleCEO
- +25Trade size$6.0M at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.9%, 3m +6.7%, 6m -16.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000361, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,200 | $73.64 | $530k | 628,486 | Apr 13, 2026 |
| Apr 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,300 | $74.60 | $395k | 623,186 | Apr 13, 2026 |
| Apr 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,500 | $75.55 | $567k | 615,686 | Apr 13, 2026 |
| Apr 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,072 | $73.64 | $521k | 4,431,375 | Apr 13, 2026 |
| Apr 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,128 | $74.57 | $382k | 4,426,247 | Apr 13, 2026 |
| Apr 9, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -7,800 | $75.53 | $589k | 4,418,447 | Apr 13, 2026 |
| Apr 10, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -20,000 | $74.60 | $1.5M | 595,686 | Apr 13, 2026 |
| Apr 10, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -20,000 | $74.60 | $1.5M | 4,398,447 | Apr 13, 2026 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 35Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.7M 44,980 shares | -16% | |
| 6Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $160k 2,000 shares | -2% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $13M 148,589 shares | -95% | |
| 23Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $1.4M 17,167 shares | -43% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.